tiprankstipranks
Cidara Therapeutics Inc. (CDTX)
:CDTX
US Market
CDTX
Cidara Therapeutics
RESEARCH TOOLSreports

Cidara Therapeutics (CDTX) Price & Analysis

― Followers

CDTX Stock Chart & Stats

$221.38
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Cidara Therapeutics News

CDTX Upcoming Earnings Report: What to Expect?
CDTX Upcoming Earnings Report: What to Expect?
Cidara Therapeutics Inc. (CDTX) is scheduled to report 4th quarter earnings on 03/11/2026. Regarding Q4 estimates, Wall Street...
5M ago
CDTX
Cidara Therapeutics Completes Acquisition and Becomes Private Company
Cidara Therapeutics Completes Acquisition and Becomes Private Company
An announcement from Cidara Therapeutics ( ($CDTX) ) is now available. On January 7, 2026, following the expiration...
7M ago
8K
CDTX
Merck to complete acquisition of Cidara Therapeutics
Merck to complete acquisition of Cidara Therapeutics
Merck (MRK) announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding...
7M ago
MRK
CDTX
5 Stocks That Moved the Most in 2025 – What Lies Ahead
5 Stocks That Moved the Most in 2025 – What Lies Ahead
The year 2025 has been anything but quiet, and a handful of mid‑ and large‑cap names have delivered...
7M ago
RGC
ABVX
Cidara Therapeutics reaches target enrollment of Phase 3 ANCHOR trial
Cidara Therapeutics reaches target enrollment of Phase 3 ANCHOR trial
Cidara Therapeutics (CDTX) has reached target enrollment in its Phase 3 ANCHOR trial of 6,000 participants across clinical...
8M ago
CDTX
Merck price target raised to $105 from $98 at BofA
Merck price target raised to $105 from $98 at BofA
BofA analyst Tim Anderson raised the firm’s price target on Merck (MRK) to $105 from $98 and keeps...
8M ago
MRK
CDTX
Cidara Therapeutics downgraded to Neutral from Buy at Guggenheim
Cidara Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Cidara Therapeutics (CDTX) to Neutral from Buy without a price target after the company agreed to...
8M ago
CDTX
Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
Merck expects over $5B opportunity from Cidara’s flu drug, Reuters reports
Merck (MRK) said it anticipates a commercial opportunity surpassing $5B from Cidara’s (CDTX) experimental flu drug, and does...
8M ago
MRK
CDTX
Cidara Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Cidara Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Maxwell Skor downgraded Cidara Therapeutics (CDTX) to Equal Weight from Overweight with a $221.50 price...
9M ago
CDTX
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
Traders will find all the latest earnings reports, economic data, and deals leading the stock market on Friday. ...
9M ago
DIA
MRK
Cidara Therapeutics downgraded to Neutral from Overweight at JPMorgan
Cidara Therapeutics downgraded to Neutral from Overweight at JPMorgan
JPMorgan downgraded Cidara Therapeutics(CDTX) to Neutral from Overweight with a $221.50 price target after the company agreed to...
9M ago
CDTX
Cidara downgraded to Sector Perform from Outperform at RBC Capital
Cidara downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Cidara Therapeutics (CDTX) to Sector Perform from Outperform with a price target of $221.50, up...
9M ago
CDTX
Midday Fly By: Walmart names new CEO, Merck acquires Cidara
Midday Fly By: Walmart names new CEO, Merck acquires Cidara
The major averages were mixed near noon, as the Dow dropped while the S&P 500 and the Nasdaq...
9M ago
HD
NU
Cidara Therapeutics downgraded to Hold from Buy at Needham
Cidara Therapeutics downgraded to Hold from Buy at Needham
Needham downgraded Cidara Therapeutics (CDTX) to Hold from Buy without a price target after the company agreed to...
9M ago
CDTX

CDTX FAQ

What was Cidara Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Cidara Therapeutics Inc.’s market cap?
Currently, no data Available
When is Cidara Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Cidara Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Cidara Therapeutics Inc. overvalued?
According to Wall Street analysts Cidara Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Cidara Therapeutics Inc. pay dividends?
    Cidara Therapeutics Inc. does not currently pay dividends.
    What is Cidara Therapeutics Inc.’s EPS estimate?
    Cidara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Cidara Therapeutics Inc. have?
    Currently, no data Available
    What happened to Cidara Therapeutics Inc.’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Cidara Therapeutics Inc.?
    Currently, no hedge funds are holding shares in CDTX
    What is the TipRanks Smart Score and how is it calculated?
    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
      Popular Stocks